JPRN-jRCTs051220066招募中3 期
JCCG CNSGCT2021: A Randomized Controlled Clinical Study of Radiotherapy Combined with Chemotherapy in Patients with Newly Diagnosed Central Nervous System Germ Cell Tumor - JCCG CNSGCT2021
ARAKAWA Yoshiki0 个研究点目标入组 380 人开始时间: 2022年7月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 380
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Registration criteria
- •1) Diagnosed as newly diagnosed central nervous system germ cell tumor in pathological diagnosis, or clinically proven diagnosis of central nervous system germ cell tumor.
- •2) Registered in the observational study for pediatric solid tumors by Japan Children's Oncology Group (JCCG).
- •3) Any age
- •4) No prior chemotherapy or head radiation therapy for any intracranial tumors.
- •5) Written informed consent is obtained from the patient or his/her legal guardian.
- •Germinoma stratum
- •1) Diagnosed as germinoma in pathological diagnosis.
- •2) 3 years or older, less than 30 years.
- •3) Serum alpha-fetoprotein (AFP)<10 ng/mL and human chorionic gonadotropin (HCG)<200mIU/ml.
- •4) No spinal dissemination.
- •5) Protocol treatment can be started within 6 weeks after surgery .
- •6) ECOG performance status (PS) of 0, 1, 2, or 3 due to neurological signs caused by the tumor.
- •7) The following conditions are met within 14 days prior to registration.
- •1. WBC>=2000/microliter and neutrophil >=1000/microliter
- •2. PLT>=100,000/microliter
- •3. AST<=100IU/L
- •4. D-Bil<=1.0mg/dl
- •5. Serum creatinine level is below the upper limit of normal value
- •Malignant germ cell tumor stratum
- •1) Diagnosed as malignant germ cell tumor (yalk sac tumor, embryonal carcinoma, choriocarcinoma) in pathological diagnosis or mixed with malignant germ cell tumor or clinically diagnosed as malignant germ cell tumor with serum AFP>=250 ng/mL or HCG >=500mIU/ml.
- •2) 3 years or older, less than 30 years.
- •3) No multiple tumors.
- •4) No dissemination.
- •5) Protocol treatment can be started within 6 weeks after surgery or cllinial diagnosis.
- •6) ECOG performance status (PS) of 0, 1, 2, or 3 due to neurological signs caused by the tumor.
- •7) The following conditions are met within 14 days prior to registration
- •1. WBC>=2000/microliter and neutrophil >=1000/microliter
- •2. PLT>=100,000/microliter
- •3. AST<=100IU/L
- •4. D-Bil<=1.0mg/dl
- •5. Serum creatinine level is below the upper limit of normal value
- •Prospective observation stratum
- •1) Diagnosed pathologically or clinically diagnosed as germ cell tumor except for germinoma stratum and malignant germ cell tumor stratum
- •2) At any age
- •3) Regardless of tumor location, number, and dissemination
排除标准
- •Germinoma stratum and malignant germ cell tumor stratum
- •1) Active double cancer (synchronous double cancer and metachronous double cancer with disease-free period of 5 years or less).
- •2) Complicated with extracranial metastasis.
- •3) Complicated heart disease requiring treatment.
- •4) Pregnant or nursing.
- •Prospective observation stratum
- •1) Judgement of inappropriate inclusion by physician
研究者
相似试验
招募中
3 期
JCOG2011: A randomized controlled phase III trial for confirming superiority of local radiotherapy added to anti-androgen therapy for prostate cancer patients with high volume metastasis sensitive to hormone therapyhigh volume metastatic prostate cancerJPRN-jRCT1031220676KAMOTO Toshiyuki440
招募中
3 期
JCOG2207: A phase III randomized controlled trial comparing total mesorectal excision and lateral lymph node dissection plus adjuvant chemotherapy with total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for the patients with locoregionally advanced low rectal cancerRectal cancerJPRN-jRCTs031230415OHUE Masayuki420
招募中
3 期
JCOG1801: A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancerresectable locally recurrent rectal cancerJPRN-jRCTs031190076Ito Masaaki110
招募中
3 期
JCOG2206: A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomyEsophageal squamous cell carcinoma with no pathological complete response after neoadjuvant therapyJPRN-jRCTs031230219KITAGAWA Yuko450
进行中（未招募）
3 期
JCOG2007: A Multicenter Randomized Phase III Study comparing Pembrolizumab + Platinum Combination Chemotherapy with Nivolumab + Ipilimumab + Platinum Combination Chemotherapy for Treatment-naive Advanced Non-Small Cell Lung Cancer without Driver Gene alteratioTreatment-naive advanced non-small cell lung cancer without driver gene alterationNSCLC, advanced, driver oncogene negativeD002289JPRN-jRCTs031210013OKAMOTO Isamu422